Pharmaceutical News

RSS

Study examines rate of psychotropic medication prescribed to children in Kentucky

Researchers with the Child and Adolescent Health Research Design and Support Unit (CAHRDS Unit) at the University of Louisville have begun a study to examine one of Kentucky's most vexing children's health issues: the higher-than-average rate of psychotropic medication being prescribed to children in the Bluegrass State.

2 Dec 2014

Antacid medicines improve overall survival in patients with head and neck cancer

Patients with head and neck cancer who used antacid medicines to control acid reflux had better overall survival, according to a new study from the University of Michigan Comprehensive Cancer Center.

2 Dec 2014

Otsuka Pharmaceutical to acquire Avanir Pharmaceuticals for $3.5B

Avanir Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement with Otsuka Pharmaceutical Co., Ltd. pursuant to which Otsuka will acquire Avanir for $17.00 per share in cash.

2 Dec 2014

Co-enzyme Q supplement lowers age-associated damage that leads to heart disease

New research involving rats, and published in the December 2014 issue of The FASEB Journal, suggests that if you were born at a low birth weight, supplemental co-enzyme Q (CoQ) may lower your risk for heart disease.

2 Dec 2014

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast and colon cancers, according to two studies led by researchers at the Icahn School of Medicine at Mount Sinai and published today in the Proceedings of the National Academy of Sciences.

2 Dec 2014

Ligand indazole chloride improves motor function, study shows

Multiple sclerosis (MS), an autoimmune disease of the brain and spinal cord, affects about 2.3 million people worldwide (400,000 in the United States). Affecting more women than men, it can be seen at any age, although it is most commonly diagnosed between the ages of 20 and 40.

2 Dec 2014

Antibiotic resistance: Theme for next Uppsala Health Summit

The theme for the next Uppsala Health Summit, to be held in Uppsala on 2-3 June 2015, is antibiotic resistance -- one of the biggest global health challenges of our day.

2 Dec 2014

Pain medicine specialist receives award for new advances in oral fluid testing

This year's Eastern Pain Society Scientific meeting was held at Mount Sinai Beth Israel Medical Center in New York City in late October and is one of the largest meetings of pain physicians and fellows in the tri-state area.

2 Dec 2014

Researchers warn that Vitamin A deficiency can cause eye problems

Obese patients who have undergone bariatric surgery to shed weight should take the supplements prescribed to them to protect their eyes. Taking in too little Vitamin A, in particular, could in some cases actually cause night blindness, dry eyes, corneal ulcers, and in extreme cases total blindness. This advice comes from Rui Azevedo Guerreiro and Rui Ribeiro of the Centro Hospitalar de Lisboa Central in Portugal, who reviewed what little research there currently is on the occurrence of eye conditions following bariatric surgery.

2 Dec 2014

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Nektar Therapeutics reported that partner Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].

From Baxter International Inc. 1 Dec 2014

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO).

1 Dec 2014

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF) as both a single agent product and in combination with other drugs.

1 Dec 2014

Clementia's palovarotene receives FDA Fast Track designation for FOP treatment

Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).

1 Dec 2014

Australian Prescriber publishes top 10 subsidised drugs in Australia

The annual publication of the top 10 subsidised drugs appears in the December edition of Australian Prescriber. Statins (cholesterol-lowering medicines) top the lists again.

1 Dec 2014

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Pharmacyclics, Inc.today announced the acceptance of a Type II variation application for IMBRUVICA (ibrutinib) by the European Medicines Agency.

1 Dec 2014

New active substance effectively combats Philadelphia chromosome-positive leukaemia

Haematologists from Goethe University Frankfurt, working with a Russian pharmaceutical company, have developed a new active substance that effectively combats the most aggressive forms of Philadelphia chromosome-positive leukaemia.

29 Nov 2014

Researchers investigate FDA influence for improving pivotal drug studies

An examination of the potential interaction between pharmaceutical companies and the U.S. Food and Drug Administration (FDA) to discuss future studies finds that one-quarter of recent new drug approvals occurred without any meeting, and when such meetings occurred, pharmaceutical companies did not comply with one-quarter of the recommendations made by the FDA regarding study design or primary outcome, according to a study in the November 26 issue of JAMA.

28 Nov 2014

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

A promising experimental immunotherapy drug works best in patients whose immune defenses initially rally to attack the cancer but then are stymied by a molecular brake that shuts down the response, according to a new study led by researchers at Dana-Farber Cancer Institute and the Yale University School of Medicine.

28 Nov 2014

Canada's current vitamin D intake recommendations need to be re-evaluated: Study

New research finds that current national vitamin D intake recommendations are too low and that body weight must be taken into account to determine the appropriate vitamin D dose in any given individual. This is currently not the case, posing a serious Canadian public health issue with significant cost and health impacts.

27 Nov 2014

Hovione submits first IND Application with FDA for minocycline gel

Hovione announced today it has filed its first Investigational New Drug (IND) Application with the U.S. Food and Drug Administration. This event represents a milestone in Hovione's strategy of developing improved drug delivery options for established drugs.

27 Nov 2014

Pharmaceutical News

Study examines rate of psychotropic medication prescribed to children in Kentucky

Antacid medicines improve overall survival in patients with head and neck cancer

Otsuka Pharmaceutical to acquire Avanir Pharmaceuticals for $3.5B

Co-enzyme Q supplement lowers age-associated damage that leads to heart disease

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

Ligand indazole chloride improves motor function, study shows

Antibiotic resistance: Theme for next Uppsala Health Summit

Pain medicine specialist receives award for new advances in oral fluid testing

Researchers warn that Vitamin A deficiency can cause eye problems

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Eylea receives Health Canada approval for treatment of CRVO and DME

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Clementia's palovarotene receives FDA Fast Track designation for FOP treatment

Australian Prescriber publishes top 10 subsidised drugs in Australia

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

New active substance effectively combats Philadelphia chromosome-positive leukaemia

Researchers investigate FDA influence for improving pivotal drug studies

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

Canada's current vitamin D intake recommendations need to be re-evaluated: Study

Hovione submits first IND Application with FDA for minocycline gel

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News